How those diabetes and weight loss drugs may be helping hearts

Embargoed until: Publicly released: 2024-07-30 04:00

Australia; International; VIC

Credit: CristianCamiloAcevedoOrozco, https://commons.wikimedia.org/wiki/File:Pluma_inyectable_de_liraglutida.jpg, CC BY-SA 4.0 <https://creativecommons.org/licenses/by-sa/4.0>, via Wikimedia Commons

People with diabetes who received a drug in the same group of diabetes/weight loss drugs as Ozempic - a glucagon-like peptide-1 receptor agonist (GLP-1 RA) called liraglutide - improved key markers of heart health, according to international and Australian research. The researchers found that, compared to another type of diabetes drug, those taking liraglutide for 16 weeks improved key measures of heart health. These measures are thought to point to potential ways that heart disease develops in type 2 diabetes. The researchers say the effects of liraglutide on these measures offer important insights into how these drugs might be having beneficial effects on heart disease as well as diabetes.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research American College of Cardiology, Web page Please link to the article in online versions of your report (the URL will go live after the embargo ends).

Editorial / Opinion American College of Cardiology, Web page Please link to the article in online versions of your report (the URL will go live after the embargo ends).

Journal/
conference: Journal of the American College of Cardiology

Research:Paper

Organisation/s: Baker Heart and Diabetes Institute, Monash University, The University of Melbourne, University of Leeds, UK

Funder: This independent research has been jointly funded by the Wellcome Trust (grant number: 221690/Z/20/Z) and Diabetes UK (grant number:18/0005870) and has been performed at the National Institute for Health and Care Research (NIHR) Leeds Biomedical Research Centre (BRC) (NIHR203331). Funding for open access charge is from Wellcome Trust (grant number: 221690/Z/20/Z). Dr Chowdhary has received grants from the British Heart Foundation (grant number: FS/CRTF/20/24003). Dr Valkovic has received grants from the Sir Henry Dale Fellowship supported jointly by the Wellcome Trust and the Royal Society (#221805/Z/20/Z), and Slovak Grant Agencies VEGA (#2/0004/23) and APVV (#21-0299). Dr Levelt acknowledges support from the Wellcome Trust Clinical Career Development Fellowship (grant number: 221690/Z/20/Z), Diabetes UK (grant number: UK 18/0005908) and the NIHR Leeds Biomedical Research Centre.

Media Contact/s

Contact details are only visible to registered journalists.